Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx (acquired by Takeda Pharmaceutical Company), Achaogen (NASDAQ: AKAO), Kythera Biopharmaceuticals (NASDAQ: KYTH, acquired by Allergan), Sapphire Energy and Unity Biotechnology.

[1][10] He served as Chief Science Officer of Kythera while the company created a now-FDA-approved injectable drug Kybella that triggers the selective destruction of fat cells.

[16][15] The U.S. Food and Drug Administration (FDA) approved plazomicin for adults with complicated UTIs and limited or no alternative treatment options in 2018; it is now sold under the brand name Zemdri.

[19] In 2010, the company began construction of the world's first commercial algal bio-refinery, a project that was awarded more than $100 million in federal funding.

[20][21] In 2011, David co-founded Unity Biotechnology (NASDAQ: UBX),[22] a company dedicated to lengthening human healthspan by selectively clearing senescent cells from the body.